MicroRNA dysregulation in colon cancer microenvironment interactions: The importance of small things in metastases

Cancer Microenvironment

Volumn 4, Issue 2, 2011, Pages 155-162

  Pucci, Sabina ^a   Mazzarelli, Paola ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Colon cancer metastasis; CPTIA; Epigenetic regulation; IL 6; Ku70 80; miRNA; VEGF A165

Indexed keywords

INTERLEUKIN 6; MICRORNA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A165A; VASCULOTROPIN A;

ARTICLE; CANCER GROWTH; CELL METABOLISM; CELL PROLIFERATION; COLON CANCER; COLON CARCINOGENESIS; COMPLEX FORMATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC EPIGENESIS; HUMAN; METASTASIS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 81855175353     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0062-y     Document Type: Article

References (73)

1. Jass JR (2006) Colorectal cancer: a multipathway disease. Crit Rev Oncog 12:273-287 (Pubitemid 46524134)
2. Finlay GJ (1993) Genetics, molecular biology and colorectal cancer. Mutat Res 290:3-12 (Pubitemid 23319751)
3. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, Dash C, Giardiello FM, Glick S, Levin TR, Pickhardt P, Rex DK, Thorson A, Winawer SJ (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58:130-160 (Pubitemid 351830299)
4. Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, Fujiwara T, Jen J, Kinzler KW, Wyllie AH, Vogelstein B, Dunlop MG et al (1995) Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med 1:348-352
5. Bousserouel S, Kauntz H, Gossé F, Bouhadjar M, Soler L, Marescaux J, Raul F (2010) Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 36(6):1485-1490
6. De Wever O, Mareel MJ (2003) Role of tissue stroma in cancer cell invasion. J Pathol 200:429-447 (Pubitemid 36818244)
7. Bates RC, Mercurio AM (2005) The epithelial-mesenchymal transition (EMT) and colorectal cancer progression. Cancer Biol Ther 4:365-370 (Pubitemid 41351251)
8. Itzkowitz SH (2006) Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 35:553-571 (Pubitemid 44307575)
9. Harpaz N, Polydorides AD (2010) Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 134:876-895
10. Scheller J, Ohnesorge N, Rose-John S (2006) Interleukin-6 transsignalling in chronic inflammation and cancer. Scand J Immunol 63:321-329
11. Keller ET, Wanagat J, Ershler WB (1996) Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1:340-357
12. Lewis AM, Varghese S, Xu H, Alexander HR (2006) Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4:48
13. Massaguè J (2008) TGFβ in cancer. Cell 134:215-230
14. Tian M, Schiemann WP (2009) The TGF-beta paradox in human cancer: an update. Future Oncol 5:259-271
15. Soufla G, Porichis F, Sourvinos G, Vassilaros S, Spandidos DA, De Wever O, Mareel M (2006) Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. Role of tissue stroma in cancer cell invasion. Cancer Lett 235:100-113
16. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848-851 (Pubitemid 38174665)
17. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732 (Pubitemid 37328811)
18. Lucarini G, Zizzi A, Belvederesi L, Kyriakidou K, Mazzucchelli R, Biagini G (2007) Increased VEGF165 expression in HCT116 colon cancer cells after transient transfection with a GFP vector encoding HIF-1 gene. J Exp Clin Cancer Res 26:515-519 (Pubitemid 351157869)
19. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 77:998-1002 (Pubitemid 28101792)
20. Faber C, Kirchner T, Hlubek F (2009) The impact of microRNAs on colorectal cancer. Virchows Arch 454:359-367
21. Heneghan HM, Miller N, Kerin MJ (2010) Systemic microRNAs: novel biomarkers for colorectal and other cancers? Gut 59:1002-1004
22. Valeri N, Croce CM, Fabbri M (2009) Pathogenetic and clinical relevance of microRNAs in colorectal cancer. Cancer Genomics Proteomics 6(4):195-204
23. Bandrés E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J (2009) Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125:2737-2743
24. Balaguer F, Link A, Lozano JJ, Cuatrecasas M, Nagasaka T, Boland CR, Goel A (2010) Epigenetic silencing ofmiR-137isan early event in colorectal carcinogenesis. Cancer Res 70(16):6609-6618
25. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297
26. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, Sharon E, Spector Y, Bentwich Z (2005) Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 37:766-770 (Pubitemid 41754896)
27. Shomron N, Golan D, Hornstein E (2009) An evolutionary perspective of animal microRNAs and their targets. J Biomed Biotechnol 2009:594738
28. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6:857-866 (Pubitemid 44629897)
29. Dykxhoorn DM (2010) MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 70(16):6401-6406
30. Iorio MV, Piovan C, Croce CM (2010) Interplay between microRNAs and the epigenetic machinery: an intricate network. Biochim Biophys Acta 1799(10-12):694-701
31. Difilippantonio MJ, Zhu J, Chen HT, Meffre E, Nussenzweig MC, Max EE et al (2000) DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 404:510-514 (Pubitemid 30186895)
32. Mitsuyama K, Matsumoto S, Masuda J, Yamasakii H, Kuwaki K, Takedatsu H, Sata M (2007) Therapeutic strategies for targeting the IL-6/STAT3 cytokine signalling pathway in inflammatory bowel disease. Anticancer Res 27:3749-3756 (Pubitemid 47598440)
33. Jarnicki A, Putoczki T, Ernst M (2010) Stat3: linking inflammation to epithelial cancer-more than a "gut" feeling? Cell Div 5:14
34. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121(Pt 20):3487-3495
35. Qiu Y, Hoareau-Aveilla C, Oltean S, Harper SJ, Bates DO (2009) The anti-angiogenic isoforms of VEGF in health and disease. Biochem Soc Trans 37(Pt 6):1207-1213
36. Pucci S, Mazzarelli P, Sesti F, Boothman DA, Spagnoli LG (2009) Interleukin-6 affects cell death escaping mechanisms acting on Bax-Ku70-Clusterin interactions in human colon cancer progression. Cell Cycle 8:473-481
37. Pucci S, Bonanno E, Sesti F, Mazzarelli P, Mauriello A, Ricci F, Zoccai GB, Rulli F, Galatà G, Spagnoli LG (2009) Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 104:2807-2815
38. Pucci S, Mazzarelli P, Nucci C, Ricci F, Spagnoli LG (2009) CLU "in and out": looking for a link. Adv Cancer Res 105:93-113
39. Mazzarelli P, Pucci S, Spagnoli LG (2009) CLU and colon cancer. The dual face of CLU: from normal to malignant phenotype. Adv Cancer Res 105:45-61
40. Gentner B, Wein A, Croner RS, Zeittraeger I, Wirtz RM, Roedel F, Dimmler A, Dorlaque L, Hohenberger W, Hahn EG, Brueckl WM (2009) Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. Anticancer Res 29:67-74
41. Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E et al (2007) Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99:309-321 (Pubitemid 47078727)
42. Pulkkinen K, Malm T, Turunen M, Koistinaho J, Ylä-Herttuala S (2008) Hypoxia induces microRNA miR-210 in vitro and in vivo ephrin-A3 and neuronal pentraxin 1 are potentially regulated by miR-210. FEBS Lett 582:2397-2401
43. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M (2008) A microRNA component of the hypoxic response. Cell Death Differ 15:667-671 (Pubitemid 351405070)
44. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC (2001) Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 167:3545-3549 (Pubitemid 32910793)
45. Gregory PA, Bracken CP, Bert AG, Goodall GJ (2008) Micro-RNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 7:3112-3118
46. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060-5072
47. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28:1714-1724
48. Kim DH, Kim M, Kwon HJ (2003) Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. J Biochem Mol Biol 36:110-119 (Pubitemid 36836262)
49. Esteller M, Villar-Garea A (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112:171-178 (Pubitemid 39244355)
50. Mariadason JM (2008) HDACs and HDAC inhibitors in colon cancer. Epigenetics 3:28-37 (Pubitemid 351540961)
51. Menendez JA, Decker JP, Lupu R (2005) In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem 94:1-4 (Pubitemid 41420319)
52. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI (2010) MicroRNA-370 controls the expression of MicroRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 51(6):1513-1523
53. Mazzarelli P, Pucci S, Bonanno E, Sesti F, Calvani M, Spagnoli LG (2007) Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation? Cancer Biol Ther 6:1606-1613 (Pubitemid 351590333)
54. Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 24:3574-3582 (Pubitemid 40756227)
55. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102:165-172
56. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature 7:763-777 (Pubitemid 47469806)
57. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan M (2007) A microRNA signature of hypoxia. Mol Cell Biol 27(5):1859-1867
58. Donker RB, Mouillet JF, Nelson DM, Sadovsky Y (2007) The expression of Argonaute2 and related microRNA biogenesis proteins in normal and hypoxic trophoblasts. Mol Hum Reprod 13(4):273-279 (Pubitemid 46554745)
59. Akao Y, Nakagawa Y, Naoe T (2006) Let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29(5):903-906
60. Tsuchiya N, Nakagama H (2010) MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutat Res 693(1-2):94-100
61. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ (2003) Reduced accumulation of specific microRNAs in colorectal neoplasia. Cancer Res 1(12):882-891 (Pubitemid 37288707)
62. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39(4):493-506
63. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H (2008) MicroRNA-21 (miR-21) posttranscriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15):2128-2136 (Pubitemid 351485639)
64. Tili E, Michaille JJ, Alder H, Volinia S, Delmas D, Latruffe N, Croce CM (2010) Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells. Biochem Pharmacol 80(12):2057-2065
65. Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M, García-Foncillas J (2006) Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. J Mol Cancer 5:29
66. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E, Raymond CK, Roberts BS, Juhl H, Kinzler KW, Vogelstein B, Velculescu VE (2006) The colorectal microRNAome. Proc Natl Acad Sci USA 103(10):3687-3692 (Pubitemid 43376616)
67. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M (2009) Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9:374
68. Xu H, Cheung IY, Guo HF, Cheung NK (2009) MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 69(15):6275-6281
69. Wang YX, Zhang XY, Zhang BF, Yang CQ, Chen XM, Gao HJ (2010) Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis. J Dig Dis 11:50-54
70. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM (2010) Reprogramming of miRNA networks in cancer and leukemia. Genome Res 20(5):589-599
71. Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez- Céspedes M, Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, Gallagher WM, Eccles SA, Croce CM, Esteller M (2008) A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 105(36):13556-13561
72. Deng S, Calin GA, Croce CM, Coukos G, Zhang L (2008) Mechanisms of microRNA deregulation in human cancer. Cell Cycle 7(17):2643-2646
73. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y (2006) MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 1:e116